Replies to post #6466 on Cel Sci Corporation (CVM)

[Foxwoods Man]

Hmmm...maybe we weren't the only ones in the dark:

From an analyst report dated October 1, 2014:

Phase III trial targets $6 Billion market......
6 programs in trials......
Patient enrolment trends for largest Phase III trial in the world for head and neck cancer.....
On Track to Complete Patient Enrolment in 2015

Outlook
We used a very conservative Discounted Cash Flow model to reach our
target price for CVM. Although CVM has programs in preclinical, Phase I, and a recently completed Phase II studies, for non-
head and neck cancer indications, we did not include any of these in our valuation metrics. We also did not include in the valuation a potential $50 Million windfall the company may receive if it wins its arbitration case against its former CRO.

Arbitration was not in the picture at all. The trial was given court approval to proceed in August of 2014 which means the trial route was a decision made by CVM waaaay before that.

I wonder what other secrets Geert has hidden....